Aragen inks deal with Innovent; Lonza and Teva think twice about biologics JV;

> Aragen Bioscience, a Bay Area CRO, has signed on with Innovent Biologics to provide the drugmaker with manufacturing cell lines for biotherapeutic product development. Release

> CRO Novum Pharmaceutical Research Services is opening a 55,000-square-foot, 225-bed facility in Houston to handle Phase I-IV clinical trials. More

> CMO Lonza and drugmaker Teva ($TEVA) are re-evaluating their joint venture to develop, manufacture and sell biosimilars, fretting over regulatory uncertainty. Story

> Parexel International's ($PRXL) Perceptive Informatics unit is launching a new version of its Impact clinical trial management software, touting improved data entry and site monitoring features. News

> Clinilabs is launching a subject-authentication initiative at its Phase I sites, using the Verified Clinical Trials database to prevent dual patient enrollment. Report

> SynteractHCR has appointed a new CIO, CMO and vice president of regulatory affairs. More

 

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.